Correlation of MiRNA and VEGF Expression with the Outcome of Early-onset Severe Preeclampsia in Patients Receiving Expectant Treatment

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Jan 16

PMID 31938323

Authors

Li Han

Yin Zhao

Zhishan Jin

Yanhui Li

Li Zou

Affiliations

Soon will be listed here.

Abstract

The present study was planned to explore the relationship between miRNA and VEGF expression in serum as well as placenta tissue with the outcome of early-onset severe preeclampsia (EOSP) in patients receiving expectant treatment. Sixty EOSP patients who had expectant treatment indications were divided into the success group (n = 46) and the failure group (n = 14) according to the pregnancy outcomes. miR-210 and miR-155 expression levels were studied in serum, ante partum, and in placenta tissue. The vascular endothelial growth factor (VEGF) and soluble VEGF receptor 1 (sFlt-1) expression levels were also explored. miR-210 and miR-155 expression levels in serum and placenta tissue before treatment, ante partum, and after accouchement of the success group were significantly lower than those of the failure group. Further, VEGF expression levels in serum and placenta tissue before treatment, ante partum, and after accouchement of the success group were significantly higher than those of the failure group. However, sFlt-1 expression levels in the success group showed a decrease in comparison to the failure group. The increase of miR-210, miR-155 levels, sFlt-1 levels, and the decrease of VEGF levels in EOSP patients might be correlated with the failure of expectant treatment.

References

Suzuki S, Shimada M, Shibata-Hiraizumi Y . Clinical trial of expectant management of severe preeclampsia that develops at <32 weeks' gestation at a Japanese perinatal center. J Matern Fetal Neonatal Med. 2013; 27(15):1568-71. DOI: 10.3109/14767058.2013.870548. View

Bueno-Sanchez J, Agudelo-Jaramillo B, Escobar-Aguilerae L, Lopera A, Cadavid-Jaramillo A, Chaouat G . Cytokine production by non-stimulated peripheral blood NK cells and lymphocytes in early-onset severe pre-eclampsia without HELLP. J Reprod Immunol. 2013; 97(2):223-31. DOI: 10.1016/j.jri.2012.11.007. View

Dekker G . Management of preeclampsia. Pregnancy Hypertens. 2015; 4(3):246-7. DOI: 10.1016/j.preghy.2014.04.021. View

Hentges C, Silveira R, Ferrelli R, Procianoy R . Influence of maternal pre-eclampsia on VEGF/PlGF heterodimer levels in preterm infants. J Matern Fetal Neonatal Med. 2014; 28(18):2166-71. DOI: 10.3109/14767058.2014.980231. View

Tong C, Xing X, Qiao S, Liu L, Shan L . [Effect of Low Molecular Weight Heparin Calcium Combined Compound Danshen Injection on Perinatal Outcomes of Nephrotic Syndrome Patients with Early Onset Severe Pre-eclampsia]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015; 35(8):957-61. View

Carney E . Hypertension: sFlt-1 removal seems to be beneficial in women with pre-eclampsia. Nat Rev Nephrol. 2015; 11(12):690. DOI: 10.1038/nrneph.2015.168. View

Cheng W, Liu T, Jiang F, Liu C, Zhao X, Gao Y . microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. Int J Mol Med. 2011; 27(3):393-9. DOI: 10.3892/ijmm.2011.598. View

Maynard S, Min J, Merchan J, Lim K, Li J, Mondal S . Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111(5):649-58. PMC: 151901. DOI: 10.1172/JCI17189. View

Yoshida A, Itoh Y, Nagaya K, Takino K, Sugawara J, Murakami T . Prolonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia: time for caution in cesarean section. J Anesth. 2006; 20(1):33-5. DOI: 10.1007/s00540-005-0354-9. View

10.

Luque A, Farwati A, Crovetto F, Crispi F, Figueras F, Gratacos E . Usefulness of circulating microRNAs for the prediction of early preeclampsia at first-trimester of pregnancy. Sci Rep. 2014; 4:4882. PMC: 4013938. DOI: 10.1038/srep04882. View

11.

Roberts J, Mascalzoni D, Ness R, Poston L . Collaboration to Understand Complex Diseases: Preeclampsia and Adverse Pregnancy Outcomes. Hypertension. 2016; 67(4):681-7. DOI: 10.1161/HYPERTENSIONAHA.115.06133. View

12.

Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides K . Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015; 45(5):584-90. DOI: 10.1002/uog.14817. View

13.

Zhao G, Zhou X, Chen S, Miao H, Fan H, Wang Z . Differential expression of microRNAs in decidua-derived mesenchymal stem cells from patients with pre-eclampsia. J Biomed Sci. 2014; 21:81. PMC: 4237795. DOI: 10.1186/s12929-014-0081-3. View

14.

Withagen M, Wallenburg H, Steegers E, Hop W, Visser W . Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia. BJOG. 2005; 112(7):910-4. DOI: 10.1111/j.1471-0528.2005.00614.x. View

15.

Wang J, Tao Y, Cheng X, Zhu T, Chen Z, Yao H . Vascular endothelial growth factor affects dendritic cell activity in hypertensive disorders of pregnancy. Mol Med Rep. 2015; 12(3):3781-3786. DOI: 10.3892/mmr.2015.3783. View

16.

Dai Y, Diao Z, Sun H, Li R, Qiu Z, Hu Y . MicroRNA-155 is involved in the remodelling of human-trophoblast-derived HTR-8/SVneo cells induced by lipopolysaccharides. Hum Reprod. 2011; 26(7):1882-91. DOI: 10.1093/humrep/der118. View

17.

Procopciuc L, Caracostea G, Zaharie G, Stamatian F . Maternal/newborn VEGF-C936T interaction and its influence on the risk, severity and prognosis of preeclampsia, as well as on the maternal angiogenic profile. J Matern Fetal Neonatal Med. 2014; 27(17):1754-60. DOI: 10.3109/14767058.2014.942625. View

18.

Kurtoglu E, Altunkaynak B, Aydin I, Ozdemir A, Altun G, Kokcu A . Role of vascular endothelial growth factor and placental growth factor expression on placenta structure in pre-eclamptic pregnancy. J Obstet Gynaecol Res. 2015; 41(10):1533-40. DOI: 10.1111/jog.12751. View

19.

Weedon-Fekjaer M, Sheng Y, Sugulle M, Johnsen G, Herse F, Redman C . Placental miR-1301 is dysregulated in early-onset preeclampsia and inversely correlated with maternal circulating leptin. Placenta. 2014; 35(9):709-17. DOI: 10.1016/j.placenta.2014.07.002. View

20.

Maebayashi Asanuma A, Yamamoto T, Azuma H, Kato E, Yamamoto N, Murase T . Expression of placenta growth factor, soluble fms-like tyrosine kinase-1, metal-responsive transcription factor-1, heme oxygenase 1 and hypoxia inducible factor-1α mRNAs in pre-eclampsia placenta and the effect of pre-eclampsia sera on their.... J Obstet Gynaecol Res. 2014; 40(10):2095-103. DOI: 10.1111/jog.12462. View